Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease

Objective: Current evidence on the immunogenicity of influenza vaccination in patients with chronic obstructive pulmonary disease (COPD) is limited. To address this need for additional knowledge, we conducted a study on the immunogenicity of trivalent seasonal influenza vaccine (TIV) in COPD patient...

Full description

Bibliographic Details
Main Authors: Yan Li, Ying Ma, Zhijie An, Chenyan Yue, Yamin Wang, Yunqiu Liu, Xiaodong Yuan, Shuping Zhang, Ming Shao, Changgui Li, Keli Li, Zundong Yin, Liye Wang, Huaqing Wang
Format: Article
Language:English
Published: Taylor & Francis Group 2021-09-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:http://dx.doi.org/10.1080/21645515.2021.1911515
_version_ 1797674506120069120
author Yan Li
Ying Ma
Zhijie An
Chenyan Yue
Yamin Wang
Yunqiu Liu
Xiaodong Yuan
Shuping Zhang
Ming Shao
Changgui Li
Keli Li
Zundong Yin
Liye Wang
Huaqing Wang
author_facet Yan Li
Ying Ma
Zhijie An
Chenyan Yue
Yamin Wang
Yunqiu Liu
Xiaodong Yuan
Shuping Zhang
Ming Shao
Changgui Li
Keli Li
Zundong Yin
Liye Wang
Huaqing Wang
author_sort Yan Li
collection DOAJ
description Objective: Current evidence on the immunogenicity of influenza vaccination in patients with chronic obstructive pulmonary disease (COPD) is limited. To address this need for additional knowledge, we conducted a study on the immunogenicity of trivalent seasonal influenza vaccine (TIV) in COPD patients. Methods: We recruited patients from respiratory outpatient clinics of three hospitals in Tangshan, Hebei province who had stable confirmed COPD, were less than 80 y old, and reported not having had influenza or receiving TIV during the study season prior to enrollment. Patients who had a history of allergy to any TIV component or were classified as having very severe COPD were excluded from the study. Eligible and consenting participants were given one dose of TIV after obtaining a baseline blood sample. A second blood sample was obtained 5 weeks later. We used hemagglutination inhibition (HI) assays to measure antibody responses. We considered seropositive to be an HI titer ≥1:10. We considered seroprotection to be an HI titer ≥1:40 and seroconversion to be either a change from seronegative to a post-vaccination titer of ≥1:40 or a fourfold rise in antibody titer among baseline seropositive subjects. Each subject was followed for 1 month to assess the frequency and type of adverse events. Results: Eighty-eight subjects completed our study; the median age was 64 y; most (62.5%) had moderately severe COPD; 48.9% of the subjects had comorbid conditions in addition to COPD. Post–vaccination seropositive rates for influenza H1N1, H3N2, and B were all 100%; corresponding seroprotection rates were 96.6%, 93.2%, and 98.9%; seroconversion rates were 81.8%, 87.5%, and 75.0%. There were no statistical differences in seroconversion (P = .10) and seroprotection (P = .30) among the three types of influenza virus. Geometric mean titers (1:) of HI antibodies to H1N1, H3N2, and B were 18.8 (95% CI: 14.0–25.1), 12.2 (95% CI: 9.6–15.4), and 31.8 (95% CI: 26.1–38.8) at baseline, and 267.0 (95% CI: 213.8–333.4), 190.3 (95% CI: 151.7–238.6), and 201.1 (95% CI: 166.5-242.8) after vaccination. Conclusion: The immunogenicity of one dose of influenza vaccine was excellent in COPD patients. Our study supports recommending influenza vaccination for COPD patients to provide protection from influenza and its complications.
first_indexed 2024-03-11T22:01:02Z
format Article
id doaj.art-c6ba2afa020e4775870296f5f6070a3b
institution Directory Open Access Journal
issn 2164-5515
2164-554X
language English
last_indexed 2024-03-11T22:01:02Z
publishDate 2021-09-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj.art-c6ba2afa020e4775870296f5f6070a3b2023-09-25T11:19:18ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-09-011793131313610.1080/21645515.2021.19115151911515Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary diseaseYan Li0Ying Ma1Zhijie An2Chenyan Yue3Yamin Wang4Yunqiu Liu5Xiaodong Yuan6Shuping Zhang7Ming Shao8Changgui Li9Keli Li10Zundong Yin11Liye Wang12Huaqing Wang13National Immunization Program, Chinese Center for Disease Control and PreventionKailuan General HospitalNational Immunization Program, Chinese Center for Disease Control and PreventionNational Immunization Program, Chinese Center for Disease Control and PreventionNational Immunization Program, Chinese Center for Disease Control and PreventionKailuan General HospitalKailuan General HospitalKailuan General HospitalNational Institute for Food and Drug ControlNational Institute for Food and Drug ControlNational Immunization Program, Chinese Center for Disease Control and PreventionNational Immunization Program, Chinese Center for Disease Control and PreventionKailuan General HospitalNational Immunization Program, Chinese Center for Disease Control and PreventionObjective: Current evidence on the immunogenicity of influenza vaccination in patients with chronic obstructive pulmonary disease (COPD) is limited. To address this need for additional knowledge, we conducted a study on the immunogenicity of trivalent seasonal influenza vaccine (TIV) in COPD patients. Methods: We recruited patients from respiratory outpatient clinics of three hospitals in Tangshan, Hebei province who had stable confirmed COPD, were less than 80 y old, and reported not having had influenza or receiving TIV during the study season prior to enrollment. Patients who had a history of allergy to any TIV component or were classified as having very severe COPD were excluded from the study. Eligible and consenting participants were given one dose of TIV after obtaining a baseline blood sample. A second blood sample was obtained 5 weeks later. We used hemagglutination inhibition (HI) assays to measure antibody responses. We considered seropositive to be an HI titer ≥1:10. We considered seroprotection to be an HI titer ≥1:40 and seroconversion to be either a change from seronegative to a post-vaccination titer of ≥1:40 or a fourfold rise in antibody titer among baseline seropositive subjects. Each subject was followed for 1 month to assess the frequency and type of adverse events. Results: Eighty-eight subjects completed our study; the median age was 64 y; most (62.5%) had moderately severe COPD; 48.9% of the subjects had comorbid conditions in addition to COPD. Post–vaccination seropositive rates for influenza H1N1, H3N2, and B were all 100%; corresponding seroprotection rates were 96.6%, 93.2%, and 98.9%; seroconversion rates were 81.8%, 87.5%, and 75.0%. There were no statistical differences in seroconversion (P = .10) and seroprotection (P = .30) among the three types of influenza virus. Geometric mean titers (1:) of HI antibodies to H1N1, H3N2, and B were 18.8 (95% CI: 14.0–25.1), 12.2 (95% CI: 9.6–15.4), and 31.8 (95% CI: 26.1–38.8) at baseline, and 267.0 (95% CI: 213.8–333.4), 190.3 (95% CI: 151.7–238.6), and 201.1 (95% CI: 166.5-242.8) after vaccination. Conclusion: The immunogenicity of one dose of influenza vaccine was excellent in COPD patients. Our study supports recommending influenza vaccination for COPD patients to provide protection from influenza and its complications.http://dx.doi.org/10.1080/21645515.2021.1911515immunogenicitysafetytrivalent seasonal influenza vaccinechronic obstructive pulmonary disease
spellingShingle Yan Li
Ying Ma
Zhijie An
Chenyan Yue
Yamin Wang
Yunqiu Liu
Xiaodong Yuan
Shuping Zhang
Ming Shao
Changgui Li
Keli Li
Zundong Yin
Liye Wang
Huaqing Wang
Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease
Human Vaccines & Immunotherapeutics
immunogenicity
safety
trivalent seasonal influenza vaccine
chronic obstructive pulmonary disease
title Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease
title_full Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease
title_fullStr Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease
title_full_unstemmed Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease
title_short Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease
title_sort immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease
topic immunogenicity
safety
trivalent seasonal influenza vaccine
chronic obstructive pulmonary disease
url http://dx.doi.org/10.1080/21645515.2021.1911515
work_keys_str_mv AT yanli immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT yingma immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT zhijiean immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT chenyanyue immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT yaminwang immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT yunqiuliu immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT xiaodongyuan immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT shupingzhang immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT mingshao immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT changguili immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT kelili immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT zundongyin immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT liyewang immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease
AT huaqingwang immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease